Form 8-K - Current report:
SEC Accession No. 0001558370-25-006760
Filing Date
2025-05-07
Accepted
2025-05-07 16:39:20
Documents
15
Period of Report
2025-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pahc-20250507x8k.htm   iXBRL 8-K 32395
2 EX-99.1 pahc-20250507xex99d1.htm EX-99.1 715204
3 GRAPHIC pahc-20250507xex99d1001.jpg GRAPHIC 8690
  Complete submission text file 0001558370-25-006760.txt   912513

Data Files

Seq Description Document Type Size
4 EX-101.SCH pahc-20250507.xsd EX-101.SCH 3407
5 EX-101.LAB pahc-20250507_lab.xml EX-101.LAB 15899
6 EX-101.PRE pahc-20250507_pre.xml EX-101.PRE 10315
17 EXTRACTED XBRL INSTANCE DOCUMENT pahc-20250507x8k_htm.xml XML 4881
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Filer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-36410 | Film No.: 25922099
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)